IO Biotech (IOBT) Competitors

IO Biotech (NASDAQ:IOBT) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations.

Which has more volatility & risk, IOBT or DRRX?

IO Biotech has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, DURECT has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in IOBT or DRRX?

54.8% of IO Biotech shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 2.3% of IO Biotech shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Is IOBT or DRRX more profitable?

IO Biotech has a net margin of 0.00% compared to DURECT's net margin of -198.58%. IO Biotech's return on equity of -86.56% beat DURECT's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IO Biotech	N/A	-86.56%	-75.24%
DURECT	-198.58%	-235.22%	-59.45%

Do analysts recommend IOBT or DRRX?

IO Biotech presently has a consensus price target of $9.33, indicating a potential upside of 1,038.21%. DURECT has a consensus price target of $5.00, indicating a potential upside of 395.05%. Given IO Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe IO Biotech is more favorable than DURECT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
DURECT	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Which has higher earnings and valuation, IOBT or DRRX?

DURECT has higher revenue and earnings than IO Biotech. DURECT is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IO Biotech	N/A	N/A	-$86.08M	-$1.37	-0.60
DURECT	$8.55M	3.67	-$27.62M	-$0.61	-1.66

Does the MarketBeat Community favor IOBT or DRRX?

DURECT received 294 more outperform votes than IO Biotech when rated by MarketBeat users. However, 91.67% of users gave IO Biotech an outperform vote while only 63.97% of users gave DURECT an outperform vote.

Company	Underperform	Outperform
IO Biotech	Outperform Votes 22 91.67%	Underperform Votes 2 8.33%
DURECT	Outperform Votes 316 63.97%	Underperform Votes 178 36.03%

Does the media prefer IOBT or DRRX?

In the previous week, IO Biotech had 9 more articles in the media than DURECT. MarketBeat recorded 16 mentions for IO Biotech and 7 mentions for DURECT. DURECT's average media sentiment score of 0.23 beat IO Biotech's score of 0.06 indicating that DURECT is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IO Biotech	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
DURECT	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

IO Biotech beats DURECT on 9 of the 17 factors compared between the two stocks.